Kezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Up 55.2% in February

Kezar Life Sciences, Inc. (NASDAQ:KZR) saw a large growth in short interest during the month of February. As of February 15th, there was short interest totalling 120,600 shares, a growth of 55.2% from the January 31st total of 77,700 shares. Currently, 1.9% of the company’s shares are sold short. Based on an average daily volume of 42,500 shares, the short-interest ratio is presently 2.8 days.

Institutional Investors Weigh In On Kezar Life Sciences

Institutional investors have recently modified their holdings of the stock. Shay Capital LLC acquired a new position in Kezar Life Sciences in the fourth quarter worth $398,000. Dimensional Fund Advisors LP bought a new stake in shares of Kezar Life Sciences in the 4th quarter worth approximately $217,000. JPMorgan Chase & Co. boosted its holdings in shares of Kezar Life Sciences by 613.8% during the fourth quarter. JPMorgan Chase & Co. now owns 11,884 shares of the company’s stock valued at $80,000 after acquiring an additional 10,219 shares during the period. BML Capital Management LLC acquired a new stake in shares of Kezar Life Sciences in the fourth quarter valued at approximately $327,000. Finally, Peapod Lane Capital LLC bought a new position in shares of Kezar Life Sciences in the fourth quarter worth $833,000. Institutional investors and hedge funds own 67.90% of the company’s stock.

Kezar Life Sciences Stock Down 3.1 %

Shares of Kezar Life Sciences stock traded down $0.18 on Friday, hitting $5.71. 123,675 shares of the company’s stock traded hands, compared to its average volume of 34,633. The company has a quick ratio of 7.65, a current ratio of 7.65 and a debt-to-equity ratio of 0.05. The firm’s 50-day moving average is $6.33 and its 200 day moving average is $6.73. The stock has a market cap of $41.66 million, a P/E ratio of -0.43 and a beta of 0.19. Kezar Life Sciences has a 52-week low of $5.20 and a 52-week high of $11.35.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. HC Wainwright reissued a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday, December 2nd. Wells Fargo & Company cut their price target on shares of Kezar Life Sciences from $11.00 to $9.00 and set an “equal weight” rating on the stock in a report on Thursday, December 19th. Finally, William Blair reaffirmed an “outperform” rating on shares of Kezar Life Sciences in a research report on Friday.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.